R-723

N/A

Report date: 2022/07/01 15:29:28
NME

Base Information

Drug NameR-723
Drug Alias NameR-723
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitors
TargetsTyrosine-protein kinase JAK2
Therapy Area/IndicationsMyeloproliferative Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRigel Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRigel Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsMyeloproliferative Disorders

Other Information

ATC CodeN/A
Related LinksN/A